| 01/11 | Glaukos Announces Positive Results for iDose TR Exchange Trial Highlighting Favorable S.. | AQ |
| 01/10 | Transcript : Glaukos Corporation Presents at 41st Annual J.P. Morgan Healthca.. | CI |
| 01/10 | Glaukos Says iDose TR Exchange Trial Shows 'Favorable' Safety, Tolerability; Shares Up .. | MT |
| 01/10 | Glaukos : Investor Presentation January 2023 | PU |
| 01/10 | Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 01/10 | Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Program.. | BU |
| 01/10 | Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable .. | BU |
| 01/10 | Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlightin.. | CI |
| 01/10 | Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipe.. | CI |
| 2022 | Glaukos Announces Participation in the J.P. Morgan Healthcare Conference 2023 | AQ |
| 2022 | Glaukos Announces Participation in the J.P. Morgan Healthcare Conference | BU |
| 2022 | Stephens Trims Price Target on Glaukos to $68 From $69, Maintains Overweight Rating | MT |
| 2022 | Mizuho Initiates Glaukos With Neutral Rating, Price Target is $48 | MT |
| 2022 | Glaukos Corp : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial .. | AQ |
| 2022 | North American Morning Briefing: Futures Waver -2- | DJ |
| 2022 | JPMorgan Upgrades Glaukos to Neutral From Underweight, Adjusts Price Target to $42 From.. | MT |
| 2022 | North American Morning Briefing: Crucial -3- | DJ |
| 2022 | Wells Fargo Adjusts Price Target on Glaukos to $44 From $56, Maintains Equal-Weight Rat.. | MT |
| 2022 | Citigroup Upgrades Glaukos to Buy From Neutral, Keeps Price Target at $57 | MT |
| 2022 | Glaukos : Investor Presentation November 2022 | PU |
| 2022 | Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Glaukos Announces Participation in the Stephens Annual Investment Conference | BU |
| 2022 | GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results
o.. | AQ |
| 2022 | Needham Adjusts Price Target on Glaukos to $65 From $66, Maintains Buy Rating | MT |
| 2022 | Piper Sandler Adjusts Glaukos' Price Target to $60 From $55, Keeps Neutral Rating | MT |
| 2022 | Glaukos : Q3 Earnings Snapshot | AQ |
| 2022 | Transcript : Glaukos Corporation, Q3 2022 Earnings Call, Nov 02, 2022 | CI |
| 2022 | Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Revenue $71.3M | MT |
| 2022 | Earnings Flash (GKOS) GLAUKOS CORPORATION Posts Q3 Loss $-0.45 | MT |
| 2022 | Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi.. | AQ |
| 2022 | Glaukos Corporation Announces Third Quarter 2022 Financial Results | BU |
| 2022 | Glaukos Corporation Revises Revenue Guidance for the Year 2022 | CI |
| 2022 | Glaukos Corporation Reports Earnings Results for the Third Quarter and Nine Months Ende.. | CI |
| 2022 | Stephens Reinstates Glaukos at Overweight With $69 Price Target | MT |
| 2022 | Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November .. | BU |
| 2022 | Needham Starts Glaukos at Buy With $66 Price Target, Citing Potential to Regain Market .. | MT |
| 2022 | Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Aca.. | BU |
| 2022 | Coupa Software, Glaukos rise; Occidental Petroleum falls | AQ |
| 2022 | Sector Update: Health Care Stocks Gaining Steam in Late Trade | MT |
| 2022 | Sector Update: Health Care Stocks Rebounding Wednesday After Long Retreat | MT |
| 2022 | Top Midday Gainers | MT |
| 2022 | Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan.. | MT |
| 2022 | Sector Update: Health Care Stocks Mixed Premarket Wednesday | MT |
| 2022 | Glaukos Says Results of Phase 3 Trials of iDose TR Met Primary Efficacy Endpoints, Plan.. | MT |
| 2022 | Glaukos Corp : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR.. | BU |
| 2022 | Glaukos Corporation Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials.. | CI |
| 2022 | Glaukos Reports 1 Million Uses of iStent Products | MT |
| 2022 | Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide | BU |
| 2022 | Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreem.. | PR |
| 2022 | Sector Update: Health Care Stocks Inching Higher Near Close | MT |
| 2022 | Sector Update: Health Care Stocks Left Grappling for Direction in Uncertai.. | MT |
| 2022 | Glaukos Announces Participation in the Wells Fargo Healthcare Conference | BU |
| 2022 | Glaukos Secures License to Investigational Corneal Disorder Treatment | MT |
| 2022 | Glaukos Licenses Iveena’S Investigational Keratoconus Therapy | CI |
| 2022 | Insider Sell: Glaukos | MT |
| 2022 | GLAUKOS CORP Management's Discussion and Analysis of Financial Condition and Results
o.. | AQ |
| 2022 | Glaukos : Q2 Earnings Snapshot | AQ |
| 2022 | Glaukos : Announces Second Quarter 2022 Financial Results - Form 8-K | PU |
| 2022 | Transcript : Glaukos Corporation, Q2 2022 Earnings Call, Aug 03, 2022 | CI |
| 2022 | Glaukos Corp : Results of Operations and Financial Condition, Regulation FD Disclosure, Fi.. | AQ |
| 2022 | Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Revenue $72.7M | MT |
| 2022 | Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q2 Loss $-1.21 | MT |
| 2022 | Glaukos Corporation Announces Second Quarter 2022 Financial Results | BU |
| 2022 | Glaukos Announces FDA 510(k) Clearance of iStent infinite® | BU |
| 2022 | Glaukos Corporation Announces FDA 510(k) Clearance of iStent Infinite | CI |
| 2022 | Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende.. | CI |
| 2022 | Glaukos Corporation Revises Sales Guidance for the Year 2022 | CI |
| 2022 | Glaukos Corporation Reports Earnings Results for the Second Quarter and Six Months Ende.. | CI |
| 2022 | Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3 | BU |
| 2022 | Sector Update: Health Care Stocks Drop on Tuesday | MT |
| 2022 | Glaukos Shares Rise After Stifel Upgrade | MT |
| 2022 | Sector Update: Health Care Stocks Drifting Lower This Afternoon | MT |
| 2022 | Stifel Upgrades Glaukos to Buy From Hold, Adjusts Price Target to $60 From $40 | MT |
| 2022 | Glaukos Corp : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
